Compared with the plethora of financial information about the publicly traded elite of the biotech world, little is known about the multitude of private biotech firms. Here, Nature Biotechnology's Editor-at-Large provides an analysis of the financial performance of the privately held biotech sector.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Critical I. Biotechnology in Europe: 2005 Comparative Study. A Critical I Comparative Study for EuropaBio, The European Association for BioIndustries (EuropaBIO, Brussels, Belgium, 2005).
Critical I. Comparative Statistics for the UK, European, and US Biotechnology Sectors: Analysis Year 2003. Report for UK Department of Trade and Industry from Critical I (UK Department of Trade and Industry, London, 2005). <http://www.dti.gov.uk/files/file28439.pdf>
Author information
Authors and Affiliations
Supplementary information
Supplementary Table 1
Mean employees per biotech company. (PDF 55 kb)
Supplementary Table 2
Median number of employees per company. (PDF 28 kb)
Rights and permissions
About this article
Cite this article
Hodgson, J. Private biotech 2004—the numbers. Nat Biotechnol 24, 635–641 (2006). https://doi.org/10.1038/nbt0606-635
Issue Date:
DOI: https://doi.org/10.1038/nbt0606-635
